#LCSM Chat 5/31/18: Lung Cancer at ASCO 2018
For the upcoming #LCSM chat on Thursday, 5/31 at 8 PM Eastern (5 PM Pacific), we’re going to preview some of the key abstracts in lung cancer and mesothelioma that will be presented at the American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago in early June. This meeting brings together over 38,000 cancer specialists every year to review thousands of presentations. Nobody can see it all, and one important aspect of not being overwhelmed is knowing what should be the focus of your attention.
Dr. Jack West has compiled two lists of abstracts he believes will reveal important findings for the thoracic oncology community. We’ll be discussing these and any other abstracts you might find interesting. Alas, ASCO begins June 1, so many thoracic oncology professionals, advocates, and patients will be en route to the conference at the time of the chat. If you won’t be able to join the chat and have an abstract you think should be discussed, please tweet it to @lcsmchat sometime before the chat so we can include it.
This won’t be the usual #LCSM Chat question and answer format. Instead, we’ll post an abstract and spend a few minutes discussing it before moving onto the next abstract.
Here are two lists of top lung cancer and mesothelioma abstracts at ASCO 2018 that will get us started:
My Top 5 ASCO 2018 Abstracts in Stage I-III NSCLC, Small Cell Lung Cancer, & Mesothelioma (OncologyTube video) by Jack West
My Top 5 ASCO 2018 Abstracts in Advanced NSCLC (OncologyTube video) by Jack West
Please remember to include #LCSM in ALL your tweets so the other chat participants can see them. If you need a refresher, read our primer on participating in the chat . Hope you’ll join us!
#LCSM Chat Topic 05/17/2018: Open Mic Night
On Thursday May 17, 2018, at 8 PM Eastern Daylight Time (5 PM Pacific Daylight Time), #LCSM Chat will hold an Open Mic Nite to talk about whatever lung cancer topics are foremost on our minds. Our moderator will be Janet Freeman-Daily (@JFreemanDaily). This would be a particularly good chat for those who are just starting with Twitter or tweet chats (please check out our tweetchat primer). Hope you’ll join us!
#LCSM Chat Topic 5/3/18: What Defines a “Quality” #LungCancer Treatment Center? Thoughts from the Frontline
Our topic for the #LCSM Tweet Chat on Thursday, May 3rd (5 PM Pacific/8 PM Eastern) is “What Defines a “Quality” #LungCancer Treatment Center? Thoughts from the Frontline.” The moderator for this chat is Dr. David Tom Cooke (@DavidCookeMD).
Recently the Centers for Medicaid and Medicare Services (CMS) announced it would cover next-generation sequencing (NGS) for US patients with stage III or IV lung cancer when ordered by a physician and performed in a CLIA-certified laboratory. This decision makes broad genomic testing to available to many more patients. Having increased access to this technology led us to ask what other services and resources should be available at a lung cancer treatment center in order for that center have a “quality” program.
We want to hear how individuals on the front lines of lung cancer—patients, family members and care providers—define a quality lung cancer treatment center. Accreditation programs such as the Commission on Cancer Accreditation and the National Cancer Institute (NCI) Comprehensive Cancer Center Designation have published their definitions. Do you agree with their definitions? Do you know of novel initiatives at your own treatment center that should be included in the definition of quality?
We will use the questions below to guide our discussion during our May 3rd Tweet Chat:
- T1) What screening services and resources should a quality #lungcancer treatment center offer? What associated qualifications/approvals should the screening program have?
- T2) What diagnostic services, tests, and resources should a quality #lungcancer treatment center offer? Should it have a multidisciplinary tumor board?
- T3) What surgical and radiosurgery services and resources should a quality #lungcancer treatment center offer?
- T5) What chemotherapy, targeted therapy, and immunotherapy treatments should a quality #lungcancer treatment center offer?
- T6) What communication services and online resources should a quality #lungcancer treatment center offer? What should be the role of telemedicine?
- T7) Must a #lungcancer treatment program offer clinical trials (or at least discuss clinical trial options) to be considered a quality program?
- T8) What patient/caregiver and/or survivorship support services should a quality #lungcancer treatment center offer? #LCSM
Please remember to include #LCSM in ALL your tweets so the other chat participants can see them. If you need a refresher, read our primer on participating in the chat . Hope you’ll join us!
